Novartis is expanding the company’s position in gene therapy and retinal diseases with the $1.5 billion acquisition of UK-based ocular gene therapy company Gyroscope Therapeutics.
Ophthalmic medical technology and pharmaceutical company Glaukos Corp. will acquire hybrid ophthalmic pharma and medical tech company Avedro Inc. in an all-stock transaction.
Janssen Pharmaceutical, a Johnson & Johnson company, inked a worldwide collaboration and license deal with MeiraGTx to develop, manufacture and commercialize a portfolio of drugs for inherited retinal diseases.
Augmented reality (AR) gained widespread attention the summer of 2016 with the addictive game Pokémon Go. But these days, AR is not just for fun. This disruptive technology is expected to drive significant changes to businesses across many industries because of its ability to combine the virtual and physical worlds.
Spark Therapeutics Inc.’s experimental gene therapy for a rare form of blindness improves vision and should be approved, advisers to the Food and Drug Administration concluded, paving the way for the first U.S. gene therapy for an inherited disease.
Spark Therapeutics Inc.’s experimental gene therapy for a rare inherited form of blindness improves vision, though it is unclear whether the benefit lasts over time, according to a preliminary review by the U.S. Food and Drug Administration.
2016 was not a banner year for M&A in the biopharma industry compared to 2014 and 2015. BioPharmaDIVE looks at seven potential acquisition targets for 2017.
Ocular Therapeutix struck a deal worth up to $315 million to develop a new formulation of Regeneron Pharmaceuticals’ approved drug Eylea.
